Chongqing Genrix Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs in China. It develops GR1501, a monoclonal antibody for the treatment of axial spondylarthritis; GR1801, an anti-rabies virus G protein bispecific antibody; GR1802, an anti-IL-4Ra monoclonal antibody; GR1603, a monoclonal antibody for systemic lupus erythematosus; GR2002 an anti-TSLP bispecific antibody; WM1R3, a family receptor bispecific antibody; GR2001, a monoclonal antibody; GR2201, a monoclonal antibody for VZV infection; GR1803, a bispecific antibody for multiple myeloma; GR1901, a bispecific antibody; WM202 a bispecific antibody; WM215, a single-domain antibody; GR1401, an anti-EGFR monoclonal antibody; and GR1405 an anti-PD-L1 monoclonal antibody. The company was founded in 2015 and is based in Chongqing, China.
Metrics to compare | 688443 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship688443PeersSector | |
---|---|---|---|---|
P/E Ratio | −16.4x | −17.4x | −0.5x | |
PEG Ratio | −2.04 | 0.56 | 0.00 | |
Price/Book | 6.2x | 6.9x | 2.6x | |
Price / LTM Sales | 246.2x | 19.8x | 3.2x | |
Upside (Analyst Target) | 18.6% | −4.4% | 42.0% | |
Fair Value Upside | Unlock | −16.6% | 6.6% | Unlock |